Research ArticleOriginal Article
Open Access

Investigation of the effect of belinostat on MCF-7 breast cancer stem cells via the Wnt, Notch, and Hedgehog signaling pathway

Zeliha Tuncer, Ercan Kurar and Tugçe Duran
Saudi Medical Journal February 2024, 45 (2) 121-127; DOI: https://doi.org/10.15537/smj.2024.45.2.20230478

References

  1. 1.↵
    1. Siegel RL,
    2. Miller KD,
    3. Fuchs HE,
    4. Jemal A
    . Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dick JE
    . Looking ahead in cancer stem cell research. Nat Biotechnol 2009; 27: 44-46.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Gottesman MM,
    2. Fojo T,
    3. Bates SE
    . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Spillane JB,
    2. Henderson MA
    . Cancer stem cells: a review. ANZ J Surg 2007; 77: 464-468.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Koren E,
    2. Fuchs Y
    . The bad seed: cancer stem cells in tumor development and resistance. Drug Resist Updat 2016; 28: 1-12.
    OpenUrl
  6. 6.↵
    1. Li Y,
    2. Atkinson K,
    3. Zhang T
    . Combination of chemotherapy and cancer stem cell targeting agents: preclinical and clinical studies. Cancer Lett 2017; 396: 103-109.
    OpenUrlCrossRef
  7. 7.↵
    1. Colvin H,
    2. Mori M
    . Getting to the heart of the matter in cancer: novel approaches to targeting cancer stem cells. Proc Jpn Acad Ser B Phys Biol Sci 2017; 93: 146-154.
    OpenUrl
  8. 8.↵
    1. Ghoncheh M,
    2. Pournamdar Z,
    3. Salehiniya H
    . Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 2016; 17: 43-46.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Wilkinson L,
    2. Gathani T
    . Understanding breast cancer as a global health concern. Br J Radiol 2022; 95: 20211033.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Dandawate PR,
    2. Subramaniam D,
    3. Jensen RA,
    4. Anant S
    . Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. Semin Cancer Biol 2016; 40-41: 192-208.
    OpenUrl
  11. 11.↵
    1. Zeng X,
    2. Liu C,
    3. Yao J,
    4. Wan H,
    5. Wan G,
    6. Li Y, et al.
    Breast cancer stem cells, heterogeneity, targeting therapies, and therapeutic implications. Pharmacol Res 2021; 163: 105320.
    OpenUrl
  12. 12.↵
    1. Manal M,
    2. Chandrasekar MJ,
    3. Gomathi Priya J,
    4. Nanjan MJ
    . Inhibitors of histone deacetylase as antitumor agents: a critical review. Bioorg Chem 2016; 67: 18-42.
    OpenUrl
  13. 13.↵
    1. Campbell P,
    2. Thomas CM
    . Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. J Oncol Pharm Pract 2017; 23: 143-147.
    OpenUrl
  14. 14.↵
    1. Apuri S,
    2. Sokol L
    . An overview of investigational histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opin Investig Drugs 2016; 25: 687-696.
    OpenUrl
  15. 15.↵
    1. Vitfell-Rasmussen J,
    2. Judson I,
    3. Safwat A,
    4. Jones RL,
    5. Rossen PB,
    6. Lind-Hansen M, et al.
    A Phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas. Sarcoma 2016; 2016: 2090271.
    OpenUrl
  16. 16.↵
    1. Kenny RG,
    2. Ude Z,
    3. Docherty JR,
    4. Marmion CJ
    . Vorinostat and belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors. J Inorg Biochem 2020; 206: 110981.
    OpenUrl
  17. 17.↵
    1. Stuver R,
    2. Epstein-Peterson ZD,
    3. Johnson WT,
    4. Khan N,
    5. Lewis N,
    6. Moskowitz AJ, et al.
    Current treatment of peripheral T-cell lymphoma. Oncology (Williston Park) 2022; 36: 293-305.
    OpenUrl
  18. 18.↵
    1. Nawaz A,
    2. Jamal A,
    3. Arif A,
    4. Parveen Z
    . In vitro cytotoxic potential of Solanum nigrum against human cancer cell lines. Saudi J Biol Sci 2021; 28: 4786-4792.
    OpenUrl
  19. 19.↵
    1. Greve B,
    2. Kelsch R,
    3. Spaniol K,
    4. Eich HT,
    5. Götte M
    . Flow cytometry in cancer stem cell analysis and separation. Cytometry A 2012; 81: 284-293.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Xu L,
    2. Zhang J,
    3. Sun J,
    4. Hou K,
    5. Yang C,
    6. Guo Y, et al.
    Epigenetic regulation of cancer stem cells: shedding light on the refractory/relapsed cancers. Biochem Pharmacol 2022; 202: 115110.
    OpenUrl
  21. 21.↵
    1. Pramanik SD,
    2. Kumar Halder A,
    3. Mukherjee U,
    4. Kumar D,
    5. Dey YN
    , R M. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. Front Chem 2022; 10: 948217.
    OpenUrl
  22. 22.↵
    1. Ma BB,
    2. Sung F,
    3. Tao Q,
    4. Poon FF,
    5. Lui VW,
    6. Yeo W, et al.
    The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs 2010; 28: 107-114.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Vinogradov S,
    2. Wei X
    . Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 2012; 7: 597-615.
    OpenUrl
  24. 24.↵
    1. Fillmore CM,
    2. Kuperwasser C
    . Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Souza FH,
    2. Wendland EM,
    3. Rosa MI,
    4. Polanczyk CA
    . Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis. Breast 2013; 22: 217-224.
    OpenUrl
  26. 26.↵
    1. Wolman SR,
    2. Heppner GH,
    3. Wolman E
    . New directions in breast cancer research. FASEB J 1997; 11: 535-543.
    OpenUrlPubMed
  27. 27.↵
    1. Hii LW,
    2. Chung FF,
    3. Soo JS,
    4. Tan BS,
    5. Mai CW,
    6. Leong CO
    . Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously. Breast Cancer Res Treat 2020; 179: 615-629.
    OpenUrl
  28. 28.↵
    1. Li X,
    2. Wang X,
    3. Xie C,
    4. Zhu J,
    5. Meng Y,
    6. Chen Y, et al.
    Sonic hedgehog and Wnt/β-catenin pathways mediate curcumin inhibition of breast cancer stem cells. Anti-cancer Drugs 2018; 29: 208-215.
    OpenUrl
  29. 29.↵
    1. Duchartre Y,
    2. Kim YM,
    3. Kahn M
    . The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol 2016; 99: 141-149.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Takebe N,
    2. Harris PJ,
    3. Warren RQ,
    4. Ivy SP
    . Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Xiao JH,
    2. Ghosn C,
    3. Hinchman C,
    4. Forbes C,
    5. Wang J,
    6. Snider N, et al.
    Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 2003; 278: 29954-29962.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. De Monte C,
    2. Carradori S,
    3. Gentili A,
    4. Mollica A,
    5. Trisciuoglio D,
    6. Supuran CT
    . Dual cyclooxygenase and carbonic anhydrase inhibition by nonsteroidal anti-inflammatory drugs for the treatment of cancer. Curr Med Chem 2015; 22: 2812-2818.
    OpenUrl
  33. 33.↵
    1. Hsieh HY,
    2. Chuang HC,
    3. Shen FH,
    4. Detroja K,
    5. Hsin LW,
    6. Chen CS
    . Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. Eur J Med Chem 2017; 140: 42-51.
    OpenUrl
  34. 34.↵
    1. Chao MW,
    2. Chu PC,
    3. Chuang HC,
    4. Shen FH,
    5. Chou CC,
    6. Hsu EC, et al.
    Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Oncotarget 2016; 7: 1796-1807.
    OpenUrlCrossRef
  35. 35.↵
    1. Kubo M,
    2. Nakamura M,
    3. Tasaki A,
    4. Yamanaka N,
    5. Nakashima H,
    6. Nomura M, et al.
    Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 2004; 64: 6071-6074.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Gruber W,
    2. Peer E,
    3. Elmer DP,
    4. Sternberg C,
    5. Tesanovic S,
    6. Del Burgo P, et al.
    Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance. Int J Cancer 2018; 142: 968-975.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Wang J,
    2. Ye C,
    3. Lu D,
    4. Chen Y,
    5. Jia Y,
    6. Ying X, et al.
    Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis. Oncotarget 2017; 8: 91379-91390.
    OpenUrl
  38. 38.↵
    1. Li J,
    2. Cai H,
    3. Li H,
    4. Liu Y,
    5. Wang Y,
    6. Shi Y, et al.
    Combined inhibition of sonic Hedgehog signaling and histone deacetylase is an effective treatment for liver cancer. Oncol Rep 2019; 41: 1991-1997.
    OpenUrl
  39. 39.↵
    1. Kelly TK,
    2. De Carvalho DD,
    3. Jones PA
    . Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-1078.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Eckschlager T,
    2. Plch J,
    3. Stiborova M,
    4. Hrabeta J
    . Histone deacetylase inhibitors as anti-cancer drugs. Int J Mol Sci 2017; 18: 1414.
    OpenUrlCrossRefPubMed
  41. 41.
    1. Okoye UC,
    2. Malbon CC,
    3. Wang HY
    . Wnt and Frizzled RNA expression in human mesenchymal and embryonic (H7) stem cells. J Mol Signal 2008; 3: 16.
    OpenUrlCrossRefPubMed
  42. 42.
    1. Zhang B,
    2. Zhou KK,
    3. Ma JX
    . Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway. Diabetes 2010; 59: 1809-1816.
    OpenUrlAbstract/FREE Full Text
  43. 43.
    1. Park MA,
    2. Kumar A,
    3. Jung HS,
    4. Uenishi G,
    5. Moskvin OV,
    6. Thomson JA, et al.
    Activation of the arterial program drives development of definitive hemogenic endothelium with lymphoid potential. Cell Rep 2018; 23: 2467-2481.
    OpenUrlCrossRef
  44. 44.
    1. You S,
    2. Zhou J,
    3. Chen S,
    4. Zhou P,
    5. Lv J,
    6. Han X, et al.
    PTCH1, a receptor of Hedgehog signaling pathway, is correlated with metastatic potential of colorectal cancer. Ups J Med Sci 2010; 115: 169-175.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords